DB-3Q for the Treatment of Medically Refractory Crohn's Disease
A Phase 2a Study of DB-3Q for the Treatment of Medically Refractory Crohn's Disease
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Bill Arana
- Telefoonnummer: 15123547124
- E-mail: barana@directbiologics.com
Studie Locaties
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University, St. Louis
-
Contact:
- Study Coordinator
- Telefoonnummer: 314-273-0301
- E-mail: luluhuang@wustl.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Written informed consent from participant
- Males and females 18-75 years of age
- Diagnosed with Crohn's disease of at least 6 months duration with medically refractory symptoms that failed to respond or responded but recurred after one advanced immunologic therapy (must have been receiving at least one advanced immunological therapy for 14 weeks duration prior to screening, including, but not limited to, adalimumab, certolizumab, , infliximab, risankizumab, upadacitinib, ustekinumab and vedolizumab), or is intolerant, or has a contraindication to advanced immunological therapy with a next step of subtotal colectomy or escalation in medical management
- Active CD as defined by a CDAI score ≥ 220 and/or SES-CD score ≥ 4
- Exposure to corticosteroids, 5-aminosalicylic acid (5-ASA) drugs, thiopurines, methotrexate, anti-TNF therapy, anti-integrin and anti-interleukin in the past are permitted but a washout period of 8 weeks for any monoclonal antibody is necessary
- If receiving conventional immunomodulators (i.e., azathioprine [AZA], mercaptopurine [6-MP], or methotrexate [MTX]), must have been taking them for ≥12 weeks, and on a stable dose for at least 4 weeks prior to initial administration of IMP
- If AZA, 6-MP, or MTX has been recently discontinued, it must have been stopped for at least 4 weeks prior to initial administration of IMP
- If receiving oral 5-ASA compounds, the dose must have been stable for at least 4 weeks. If receiving oral corticosteroids, the dose must be ≤20 mg/day prednisone or its equivalent and must have been stable for at least 4 weeks prior to initial administration of IMP
- If receiving budesonide, the dose must have been stable for at least 2 weeks prior to initial administration of IMP
- If oral 5-ASA compounds or oral corticosteroids (including budesonide) have been recently discontinued, they must have been stopped for at least 2 weeks prior to initial administration of IMP
The following medications/therapies must have been discontinued before initial administration of IMP:
- Monoclonal therapy (e.g., adalimumab, certolizumab, infliximab, risankizumab, ustenkinumab, and vedolizumab) for at least 8 weeks
- Cyclosporine, tacrolimus, or sirolimus, for at least 4 weeks
- 6-thioguanine (6-TG) must have been discontinued for at least 4 weeks
- JAK inhibitors (e.g., upadacitinib) must have been discontinued for at least 4 weeks
- Rectal corticosteroids (i.e., corticosteroids [including budesonide] administered to the rectum or sigmoid colon via foam or enema or suppository) for at least 2 weeks
- Rectal 5-ASA compounds (i.e., 5-ASAs administered to the rectum or sigmoid colon via foam or enema or suppository) for at least 2 weeks
- Parenteral corticosteroids for at least 2 weeks
- Total parenteral nutrition for at least 2 weeks
- Antibiotics for the treatment of CD (e.g., ciprofloxacin, metronidazole, or rifaximin) for at least 2 weeks
- No colonic dysplasia and malignancy as ruled out by colonoscopy within 90 days prior to initial administration of IMP
- If participant is of reproductive capacity, willing to use adequate birth control measures while in the study
Exclusion Criteria:
- Lack of informed consent
- Pregnant woman, woman of childbearing potential without a documented negative urine or serum pregnancy test, or woman who is breast feeding
- Clinically significant medical conditions within the six months before initial administration of IMP: e.g., myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the participant
- Confirmed Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C infections
- Aspartate aminotransferase (AST) or Alanine transaminase (ALT) greater than 3 times the upper limit of normal at screening
Abnormal basic laboratory values with the following cut-offs:
- Alkaline phosphate > 200 U/L
- WBC >13 109/L
- Hemoglobin < 7 g/dL
- Platelets < 50 or > 109/L
- eGFR < 60 mL/min/1.73m2
- HbA1C > 8%
- Prothrombin time (PT), partial thromboplastin time (aPTT) or international normalized ratio (INR) greater than 1.5 times the upper limits of normal at screening
Clinically significant abnormal vital signs prior to initial administration of IMP as defined by:
- Systolic blood pressure >160 or <90 mmHg
- Diastolic blood pressure >90 or <60 mmHg
- Pulse <55 or >105 bpm
- Respiratory Rate (RR) <9 and >25 breaths per minute
- Temperature >100.4 degrees Fahrenheit
- SpO2 <92%
- History of cancer including melanoma (with the exception of localized skin cancers) within 5 years of study enrollment
- Ulcerative colitis or indeterminate colitis
- Suspicion or presence of an intraabdominal or perianal abscess
- Microscopic, ischemic or infectious colitis
- Neoplasia of the colon on preoperative biopsy
- Evidence of colonic perforation
- Colonic stricture that unable to pass an adult colonoscope
- Three or more prior small bowel resections
- Presence of an ostomy
- Massive hemorrhage from the colon requiring emergent surgery in the 6 months prior to screening
- Fulminant colitis requiring emergency surgery
- Concurrent active clostridium difficile infection of the colon
- Concurrent Cytomegalovirus infection of the colon via colonic biopsy with CMV stain taken within 90 days prior to screening
- Active or latent tuberculosis
- Unable to wean off corticosteroids
- Primary sclerosing cholangitis
- History of or current alcohol or drug abuse or dependence, recreational use of illicit drugs or prescription medications, or use of medical marijuana within 90 days prior to screening
- Known allergy to local anesthetics
- Concurrent use of anticoagulant medications (e.g. warfarin, heparin) or clopidogrel (Plavix)
- History of known inherited or acquired hypercoagulable states.
- Electrocardiogram demonstrating cardiac arrhythmia, except for sinus tachycardia within the predefined limit of no greater than 105 bpm.
- Use of investigational therapy or treatment within 6 months prior to initial IMP administration
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo IV
|
0,9% zoutoplossing
|
|
Experimenteel: DB-3Q 15 mL IV
|
bmMSC derived, extracellular vesicle enriched secretome product
|
|
Experimenteel: DB-3Q 30 mL IV
|
bmMSC derived, extracellular vesicle enriched secretome product
|
|
Experimenteel: DB-3Q 45 mL IV
|
bmMSC derived, extracellular vesicle enriched secretome product
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline in SES-CD Score
Tijdsspanne: 12 Weeks
|
Simple Endoscopic Score for Crohn's Disease (SES-CD) is a standardized tool used by gastroenterologists to assess and quantify the severity of Crohn's disease during an endoscopy or colonoscopy.
The scale goes from 0 to greater than 15, with a lower score being better.
|
12 Weeks
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 3Q-CD-201
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .